Equibles does not estimate personal net worth.
Get an email with a short summary when Jazz Pharmaceuticals plc publishes a filing, an earnings call transcript or a press release.
Get JAZZ alertsRenee D. Gala is recorded as CEO at Jazz Pharmaceuticals plc (JAZZ). The proxy statement of Jazz Pharmaceuticals plc reports total compensation of $19,151,558 for Renee D. Gala in fiscal 2025, including a base salary of $1,003,269. Disclosed compensation is on record for 3 fiscal years. Renee D. Gala has spoken on 2 earnings calls across 1 company, most recently for Jazz Pharmaceuticals plc on November 2, 2026. Jazz Pharmaceuticals plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jazz Pharmaceuticals plc includes Bruce Cozadd (CEO and Board Member), Renee Gala (CEO, COO and Board Member), Matthew P. Young (CFO) and 7 others.
“Our third quarter results demonstrate the progress we are making as we build a more innovative and diversified job. We delivered record revenues of $1.24 billion, an increase of 10% year-over-year, while advancing several important drivers of our future growth.”
“We delivered another outstanding quarter, generating record revenue of $1.2 billion, representing 16% year-over-year growth. The momentum we've built in the first half of the year provides us with confidence to raise our full-year revenue guidance.”
Biotechnology · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Jazz Pharmaceuticals plc (JAZZ) | President, CEO and Director | $1,003,269 | $19,151,558 |
| 2024 | Jazz Pharmaceuticals plc (JAZZ) | President, CEO and Director | $824,923 | $6,628,888 |
| 2023 | Jazz Pharmaceuticals plc (JAZZ) | President, CEO and Director | $767,719 | $5,434,388 |
